Clinical Trial Update: Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease [Phase 3]

View source ↗

Summary

Phase 3 trial assessing safety and efficacy of several Replagal dosing regimens on cardiac function in adults with Fabry disease completed with posted results i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fabry Disease

Drugs mentioned

• Replagal (agalsidase alfa)

Snippet

Sponsor: Shire | Conditions: Fabry Disease | Phase 3 | Status: COMPLETED | Results posted: 2014-06-06